Theravance Biopharma (TBPH) Announces Positive Data from TD-0714 Phase 1 MAD Trial
Tweet Send to a Friend
Theravance Biopharma, Inc. (Nasdaq: TBPH) announced positive results, including biomarker data, from its Phase 1 multiple-ascending dose (MAD) clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
